Estrogens and cardiovascular disease risk revisited: the Women's Health Initiative

Current Opinion in Lipidology

Volumn 24, Issue 6, 2013, Pages 493-499

  Howard, Barbara V ^a,b   Rossouw, Jacques E ^c  

^a MEDSTAR RESEARCH INSTITUTE   (United States)

^b Delaware   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

cardiovascular disease; CVD risk factors; hormone therapy; Women's Health Initiative

Indexed keywords

ACETYLSALICYLIC ACID; ESTROGEN; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

AGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DRUG MECHANISM; DRUG WITHDRAWAL; HEALTH STATUS; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MENOPAUSAL SYNDROME; METABOLIC CAPACITY; METABOLIC SYNDROME X; OBESITY; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN INTAKE; REVIEW; VENOUS THROMBOEMBOLISM; WOMEN'S HEALTH;

ANIMALS; CARDIOVASCULAR DISEASES; DRUG COMBINATIONS; ESTROGENS; FEMALE; HEALTH; HORMONE REPLACEMENT THERAPY; HUMANS; RISK;

EID: 84888305389     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000022     Document Type: Review

References (35)

1. Go AS, Mozzafarian D, Roger VL, et al. Heart Disease and Stroke Statistics -2013 Update: A report from the American Heart Association. Circulation 2013; 125:E6-e245
2. Hazzard WR, Applebaum-Bowden D. Why women live longer than men: The biologic mechanism of the sex differential in longevity. Trans Am Clin Climatol Assoc 1990; 101:168-189.
3. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease and other considerations. Ann Rev Public Health 1998; 19:55-72.
4. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: Annual trends and response to recent evidence. JAMA 2004; 29:47-53.
5. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998; 280:605-613.
6. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000; 343:522-529.
7. Viscoli DM, Brass LM, Kerman WN, et al. A clinical trial of estrogenreplacement therapy after ischemic stroke. N Engl J Med 2001; 345:1243-1249.
8. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational, study. Control Clin Trials 1998; 19:61-109.
9. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Qrincipal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
10. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 2004; 291:1701-1712.
11. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative Randomized Trials. JAMA 2013; 310:1353-1368
12. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297:1465-1477.
13. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Eng J Med 2003; 349:523-534.
14. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: The Women's Health Initiative. Arch Intern Med 2006; 166:357-365.
15. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: The Women's Health Initiative: A randomized trial. JAMA 2003; 289:2673-2684.
16. Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 2006; 113:2425-2434.
17. Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004; 292:1573-1580.
18. Curb JD, Prentice RL, Bray PF, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006; 166: 772-780.
19. Rossouw JE, Prentice RL, LaCroix AZ, et al. Hormone therapy and cardiovascular risk-reply. JAMA 2007; 298:624.
20. Wild RA, WuC, Curb JD, et al. Coronary heart disease events in the Women's Health Initiative hormone trials: Effect modification by metabolic syndrome: A nested case-control study within the Women's Health Initiative randomized clinical trials. Menopause 2013; 20:254-260
21. Bray PF, Larson JC, Lacroix AZ, et al. Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events. Am J Cardiol 2008; 101: 1599-1605.
22. Rossouw JE, Cushman M, Greenland P, et al. Inflammatory, lipid, thrombotic and genetic markers of coronary heart disease risk in the Women's Health Initiative trials of hormone therapy. Arch Intern Med 2008; 168: 2245-2253
23. Kooperberg C, Cushman M, Hsia J, et al. Can biomarkers identify women at increased stroke risk? The Women's Health Intiative trials. PLoS Clin Trials 2007; 2:E18
24. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995; 273:199-208.
25. Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronaryartery calcification. N Engl J Med 2007; 356:2591-2602.
26. Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008; 299:1036-1045.
27. LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: A randomized controlled trial. JAMA 2011; 305:1305-1314
28. Barton M. Cholesterol and atherosclerosis: Modulation by oestrogen. Curr Opin Lipidol 2013; 24:214-220
29. Lobo RA. Where are we 10 years after the Women's Health Initiative? J Clin Endocrinol Metab 2013; 98:1771-1780
30. Shapiro S. Risk of cardiovascular disease in relation to the use of combined postmenopausal hormone therapy: Detection bias and resolution of discrepant findings in two Women's Health Initiative studies. Climacteric 2006; 9:416-420.
31. Salpeter SR, Walsh JM, Greyber E, Salpeter EE. Brief report: Coronary heart disease events associated with hormone therapy in younger and older women: A meta-analysis. J Gen Intern Med 2008; 21:363-366.
32. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular disease in recently menopausal women: Randomized trial. BMJ 2012; 345:E6409
33. Hsia J, Criqui MH, Herrington DM, et al. Conjugated equine estrogens and peripheral arterial disease risk: The Women's Health Initiative. Am Heart J 2006; 152:170-176.
34. Hsia J, Criqui MH, Rodabough RJ, et al. Estrogen plus progestin and the risk of peripheral arterial disease: The Women's Health Initiative. Circulation 2004; 109:620-626.
35. Klein, Lilviu, et al. submitted for publication